Shirron Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shirron Carter has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Gwendolyn M. Cramer
The Wistar Institute, Philadelphia, Pennsylvania
22 shared publications - Theresa M. Busch
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
22 shared publications - Andrew V. Kossenkov
The Wistar Institute, Philadelphia, Pennsylvania
21 shared publications - Astero Klampatsa
Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
21 shared publications - Edmund K. Moon
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
21 shared publications - Emmanouil Papasavvas
The Wistar Institute, Philadelphia, Pennsylvania
21 shared publications
Latest Publications
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Genes found by DESeq2 significantly associated with time of sample collection
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Genes found by DESeq2 significantly associated with time of sample collection
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
TI performed prior to PDT limits PDT efficacy.
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
TI performed prior to PDT limits PDT efficacy.
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
PD-1 blockade significantly decreases tumor growth rates in combination with TI/PDT. αPD-1 initiated 1 hour after PDT and continuing 2× weekly for 3 weeks did not significantly alter tumor growth rates. A, In AB12 mice, more than 50% of both PDT alone (n = 14) and PDT/aPD-1 (n = 12) had median survival (time to 400 mm3) greater than 90 days, and no differences between groups were detected (P = 0.56). B, In AE17O mice, median survivals of 33.5 days for PDT (n = 34) and 40 days for PDT/αPD-1 (n = 12) were similar (P = 0.79). C, In AB12 tumor–bearing mice that received TI prior to PDT, αPD-1 significantly decreased the rate of tumor regrowth (P = 0.005), with a median survival >90 days for TI/PDT/αPD-1 (n = 13) and 24-day median survival in TI/PDT (n = 16). TI/PDT/αPD-1 isotype control (n = 13) was also significantly different from TI/PDT/αPD-1 (P = 0.025) and similar to TI/PDT (P = 0.87). D, In AE17O tumor–bearing mice that received TI prior to PDT, αPD-1 also significantly decreased the rate of tumor regrowth (P = 0.025), with a median survival of 20.5 days for TI/PDT (n = 18) and 26 days for TI/PDT/αPD-1 (n = 20). In all tumor responses, vertical dashes indicate animals that were censored due to tumor ulceration or metastasis. Groups treated with an isotype for αPD-1 are plotted in pale orange. Tumor responses were compared using log-rank (Mantel–Cox) tests.
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
PD-1 blockade significantly decreases tumor growth rates in combination with TI/PDT. αPD-1 initiated 1 hour after PDT and continuing 2× weekly for 3 weeks did not significantly alter tumor growth rates. A, In AB12 mice, more than 50% of both PDT alone (n = 14) and PDT/aPD-1 (n = 12) had median survival (time to 400 mm3) greater than 90 days, and no differences between groups were detected (P = 0.56). B, In AE17O mice, median survivals of 33.5 days for PDT (n = 34) and 40 days for PDT/αPD-1 (n = 12) were similar (P = 0.79). C, In AB12 tumor–bearing mice that received TI prior to PDT, αPD-1 significantly decreased the rate of tumor regrowth (P = 0.005), with a median survival >90 days for TI/PDT/αPD-1 (n = 13) and 24-day median survival in TI/PDT (n = 16). TI/PDT/αPD-1 isotype control (n = 13) was also significantly different from TI/PDT/αPD-1 (P = 0.025) and similar to TI/PDT (P = 0.87). D, In AE17O tumor–bearing mice that received TI prior to PDT, αPD-1 also significantly decreased the rate of tumor regrowth (P = 0.025), with a median survival of 20.5 days for TI/PDT (n = 18) and 26 days for TI/PDT/αPD-1 (n = 20). In all tumor responses, vertical dashes indicate animals that were censored due to tumor ulceration or metastasis. Groups treated with an isotype for αPD-1 are plotted in pale orange. Tumor responses were compared using log-rank (Mantel–Cox) tests.
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Data from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Lung-sparing radical pleurectomy with intraoperative photodynamic therapy (PDT) demonstrates remarkable survival for patients with pleural mesothelioma. Nevertheless, most patients treated with this multimodal approach will develop local tumor recurrence. An understanding of potential causes of treatment failure is central to developing mitigation strategies. Surgery importantly reduces disease burden but also produces tumor-promoting inflammation, as demonstrated through transcriptomic analysis of pleural mesothelioma specimens. Using preclinical models in the setting of combination therapy, we separated the benefit of surgical resection from its counterproductive effects on therapeutic outcome. Specifically, we evaluated mechanisms by which surgically induced inflammation can be therapy-limiting in a murine model of tumor incision (TI) introduced by a surgical cut across the tumor. In this TI model, we identified distinct TI-altered patterns in innate and adaptive inflammatory cells in murine mesothelioma tumors, and we studied changes in these patterns with the addition of PDT. TI introduction of an immunosuppressive environment is established via upregulation of PD-1/PD-L1 expression on tumor cells, T cells, and myeloid cells that is partially resolved by PDT. Immune dysfunction is further mitigated by the addition of PD-1 blockade, leading to curative potential in a process that requires Ly6G+ neutrophils and CD8+ T cells. Overall, these studies suggest that, without PDT, surgical modulation of immune cell trafficking and functionality leads to systemic immunosuppression. This immunosuppressive state potentially interferes with the generation of antitumor immunity by PDT. However, targeted inhibition of surgery-induced signaling in the PD-l/PD-L1 pathway counteracts surgery’s immunosuppressive outcomes to enhance PDT efficacy in the intraoperative setting.Significance:Surgery combined with PDT extends survival for patients with mesothelioma, but these patients are still at risk for tumor recurrence, in part due to the immunosuppressive effects of surgery. We find, in a mouse model, that combining surgery, PDT, and immune checkpoint blockade maximizes the efficacy of these therapies.
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Lung-sparing radical pleurectomy with intraoperative photodynamic therapy (PDT) demonstrates remarkable survival for patients with pleural mesothelioma. Nevertheless, most patients treated with this multimodal approach will develop local tumor recurrence. An understanding of potential causes of treatment failure is central to developing mitigation strategies. Surgery importantly reduces disease burden but also produces tumor-promoting inflammation, as demonstrated through transcriptomic analysis of pleural mesothelioma specimens. Using preclinical models in the setting of combination therapy, we separated the benefit of surgical resection from its counterproductive effects on therapeutic outcome. Specifically, we evaluated mechanisms by which surgically induced inflammation can be therapy-limiting in a murine model of tumor incision (TI) introduced by a surgical cut across the tumor. In this TI model, we identified distinct TI-altered patterns in innate and adaptive inflammatory cells in murine mesothelioma tumors, and we studied changes in these patterns with the addition of PDT. TI introduction of an immunosuppressive environment is established via upregulation of PD-1/PD-L1 expression on tumor cells, T cells, and myeloid cells that is partially resolved by PDT. Immune dysfunction is further mitigated by the addition of PD-1 blockade, leading to curative potential in a process that requires Ly6G+ neutrophils and CD8+ T cells. Overall, these studies suggest that, without PDT, surgical modulation of immune cell trafficking and functionality leads to systemic immunosuppression. This immunosuppressive state potentially interferes with the generation of antitumor immunity by PDT. However, targeted inhibition of surgery-induced signaling in the PD-l/PD-L1 pathway counteracts surgery’s immunosuppressive outcomes to enhance PDT efficacy in the intraoperative setting.Significance:Surgery combined with PDT extends survival for patients with mesothelioma, but these patients are still at risk for tumor recurrence, in part due to the immunosuppressive effects of surgery. We find, in a mouse model, that combining surgery, PDT, and immune checkpoint blockade maximizes the efficacy of these therapies.
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Ly6G after TI/PDT depletion increases PD-L1 expression on Ly6C+ MDSCs
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Ly6G after TI/PDT depletion increases PD-L1 expression on Ly6C+ MDSCs
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
TI increases the proportion of AB12 tumor MDSCs and PD-L1 levels
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
TI increases the proportion of AB12 tumor MDSCs and PD-L1 levels
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
RNA sequencing experimental design
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
RNA sequencing experimental design
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Effective PD-1 blockade requires Ly6G+ myeloid cells and CD8+ T cells. A, In AB12 tumors, αLy6G initiated 1.5 hours after PDT does not significantly change tumor response (P = 0.57; PDT/αLy6G shown as dark red dotted line). For PDT, n = 14 and for PDT/αLy6G, n = 13. PDT/αLy6G isotype control (n = 13) is also not significantly different from PDT/αLy6G (P = 0.17) or from PDT alone (P = 0.65). B, In TI/PDT-treated mice, Ly6G depletion did not significantly impact the time for tumors to regrow to 400 mm3 (TI/PDT/αLy6G, n = 14, shown as pink line) The TI/PDT/αLy6G isotype control group (n = 14) is similar (P = 0.81 compared with TI/PDT/αLy6G and P = 0.42 compared with TI/PDT). C, In TI/PDT-treated mice that also received αPD-1, Ly6G depletion led to a rapid and significant decrease in mice with tumors <400 mm3 (P < 0.0002; TI/PDT/αPD-1/αLy6G, n = 13, shown as dark blue dotted line). The TI/PDT/αPD-1/αLy6G isotype control group (n = 12) is similar to TI/PDT/αPD-1 (P = 0.80) and has significantly longer survival than TI/PDT/αPD-1/αLy6G (P < 0.001). D, Flow cytometric analysis of tumor-infiltrating lymphocytes 1 day after TI/PDT/αPD-1 demonstrated that Ly6G depletion after TI/PDT/αPD-1 did not significantly change the percentage of Ly6C+ cells in the tumor (P = 0.73, left, n = 7 tumors for TI/PDT/αPD-1 and n = 6 tumors for TI/PDT/αPD-1/αLy6G). However, Ly6G depletion led to a significant increase in the PD-L1 expression on the Ly6C+ cells (P = 0.014, right). E, In AB12 tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 11, shown as pink lines) led to rapid tumor regrowth (P <0 .001 compared with TI/PDT/αPD-1). The TI/PDT/αPD-1/αCD8 isotype control group (n = 12) is similar to TI/PDT/αPD-1 (P = 0.89) and has significantly longer survival than TI/PDT/αPD-1/αCD8 (P < 0.001). F, Similarly in AE17O tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 10) also led to rapid tumor regrowth (P = 0.033 compared with TI/PDT/αPD-1). The TI/PDT/αPD-1/αCD8 isotype control group (n = 10) is similar to TI/PDT/αPD-1 (P = 0.24) and has significantly longer survival than TI/PDT/αPD-1/αCD8 (P < 0.001). Groups treated with an isotype for αLy6G or αCD8 are plotted in pale orange. Tumor responses are compared using log-rank (Mantel–Cox) tests, and all other statistical tests are by Mann–Whitney.
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Effective PD-1 blockade requires Ly6G+ myeloid cells and CD8+ T cells. A, In AB12 tumors, αLy6G initiated 1.5 hours after PDT does not significantly change tumor response (P = 0.57; PDT/αLy6G shown as dark red dotted line). For PDT, n = 14 and for PDT/αLy6G, n = 13. PDT/αLy6G isotype control (n = 13) is also not significantly different from PDT/αLy6G (P = 0.17) or from PDT alone (P = 0.65). B, In TI/PDT-treated mice, Ly6G depletion did not significantly impact the time for tumors to regrow to 400 mm3 (TI/PDT/αLy6G, n = 14, shown as pink line) The TI/PDT/αLy6G isotype control group (n = 14) is similar (P = 0.81 compared with TI/PDT/αLy6G and P = 0.42 compared with TI/PDT). C, In TI/PDT-treated mice that also received αPD-1, Ly6G depletion led to a rapid and significant decrease in mice with tumors <400 mm3 (P < 0.0002; TI/PDT/αPD-1/αLy6G, n = 13, shown as dark blue dotted line). The TI/PDT/αPD-1/αLy6G isotype control group (n = 12) is similar to TI/PDT/αPD-1 (P = 0.80) and has significantly longer survival than TI/PDT/αPD-1/αLy6G (P < 0.001). D, Flow cytometric analysis of tumor-infiltrating lymphocytes 1 day after TI/PDT/αPD-1 demonstrated that Ly6G depletion after TI/PDT/αPD-1 did not significantly change the percentage of Ly6C+ cells in the tumor (P = 0.73, left, n = 7 tumors for TI/PDT/αPD-1 and n = 6 tumors for TI/PDT/αPD-1/αLy6G). However, Ly6G depletion led to a significant increase in the PD-L1 expression on the Ly6C+ cells (P = 0.014, right). E, In AB12 tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 11, shown as pink lines) led to rapid tumor regrowth (P <0 .001 compared with TI/PDT/αPD-1). The TI/PDT/αPD-1/αCD8 isotype control group (n = 12) is similar to TI/PDT/αPD-1 (P = 0.89) and has significantly longer survival than TI/PDT/αPD-1/αCD8 (P < 0.001). F, Similarly in AE17O tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 10) also led to rapid tumor regrowth (P = 0.033 compared with TI/PDT/αPD-1). The TI/PDT/αPD-1/αCD8 isotype control group (n = 10) is similar to TI/PDT/αPD-1 (P = 0.24) and has significantly longer survival than TI/PDT/αPD-1/αCD8 (P < 0.001). Groups treated with an isotype for αLy6G or αCD8 are plotted in pale orange. Tumor responses are compared using log-rank (Mantel–Cox) tests, and all other statistical tests are by Mann–Whitney.
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Supplemental RNA sequencing analysis
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Supplemental RNA sequencing analysis
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
PDT decreases PD-L1 expression and significantly reduces tumor growth after TI. TI/PDT-treated mice had significantly longer tumor growth times (to 400 mm3) than TI mice for AB12 (P < 0.001, A) and AE17O (P < 0.001, B), with medians of 7 days for TI vs. 24 days for TI/PDT for AB12 and 13 days for TI vs. 20.5 days for TI/PDT for AE17O. In AB12 mice, n = 11 for TI and n = 16 for TI/PDT. In AE17O mice, n = 11 for TI and n = 18 for TI/PDT. C, CD11b+ Ly6G+ cells were significantly increased after TI/PDT (n = 6) compared with TI (n = 8) in AB12 tumors (P < 0.001), and their PD-L1 expression was significantly decreased following PDT (P = 0.005). D, Tumors treated with PDT (n = 6) similarly had increased Ly6G+ cells (P = 0.002) and decreased PD-L1 expression (P = 0.005) compared with TCs (n = 7). E, PDT after TI significantly decreased the proportion of Ly6G− cells (P < 0.001) and led to a significant drop in their PD-L1 levels (P = 0.008). F, The proportion of CD11b+ Ly6G− cells as a subset of CD45+ immune cells decreased significantly after PDT (P = 0.001), and their PD-L1 levels were lower on average but not significantly so (P = 0.073). G, For CD45− cells, TI/PDT led to a significant drop in the percentage of viable CD45− cells (P < 0.001) but did not alter PD-L1 expression (P = 0.30). H, PDT of CD45− cells also significantly decreased viability (P = 0.001), but no significant differences in PD-L1 expression of these cells were observed (P = 0.29). Representative gates of viable CD45− cells are shown below for each condition. I, Viable CD45− cells after TI/PDT had significantly higher levels of PD-L1 than CD45− cells after PDT alone (P = 0.004). Tumor responses (growth to 400 mm3) were compared using log-rank (Mantel–Cox) tests, and all other comparisons were made using a Mann–Whitney test. FSC-A, forward scatter area; SSC-A, side scatter area.
- 23 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
PDT decreases PD-L1 expression and significantly reduces tumor growth after TI. TI/PDT-treated mice had significantly longer tumor growth times (to 400 mm3) than TI mice for AB12 (P < 0.001, A) and AE17O (P < 0.001, B), with medians of 7 days for TI vs. 24 days for TI/PDT for AB12 and 13 days for TI vs. 20.5 days for TI/PDT for AE17O. In AB12 mice, n = 11 for TI and n = 16 for TI/PDT. In AE17O mice, n = 11 for TI and n = 18 for TI/PDT. C, CD11b+ Ly6G+ cells were significantly increased after TI/PDT (n = 6) compared with TI (n = 8) in AB12 tumors (P < 0.001), and their PD-L1 expression was significantly decreased following PDT (P = 0.005). D, Tumors treated with PDT (n = 6) similarly had increased Ly6G+ cells (P = 0.002) and decreased PD-L1 expression (P = 0.005) compared with TCs (n = 7). E, PDT after TI significantly decreased the proportion of Ly6G− cells (P < 0.001) and led to a significant drop in their PD-L1 levels (P = 0.008). F, The proportion of CD11b+ Ly6G− cells as a subset of CD45+ immune cells decreased significantly after PDT (P = 0.001), and their PD-L1 levels were lower on average but not significantly so (P = 0.073). G, For CD45− cells, TI/PDT led to a significant drop in the percentage of viable CD45− cells (P < 0.001) but did not alter PD-L1 expression (P = 0.30). H, PDT of CD45− cells also significantly decreased viability (P = 0.001), but no significant differences in PD-L1 expression of these cells were observed (P = 0.29). Representative gates of viable CD45− cells are shown below for each condition. I, Viable CD45− cells after TI/PDT had significantly higher levels of PD-L1 than CD45− cells after PDT alone (P = 0.004). Tumor responses (growth to 400 mm3) were compared using log-rank (Mantel–Cox) tests, and all other comparisons were made using a Mann–Whitney test. FSC-A, forward scatter area; SSC-A, side scatter area.